TaylorBLO’RiordanDLPantilatSZ, et al. Inpatients with neurologic disease referred for palliative care consultation. Neurology2019; 92(17): e1975–e1981.
2.
BuhseM.The elderly person with multiple sclerosis: Clinical implications for the increasing life-span. J Neurosci Nurs2015; 47(6): 333–339; quiz E1.
LundeHMBAssmusJMyhrKM, et al. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry2017; 88: 621–625.
5.
JacobsBMGiovannoniGSchmiererK.No evident disease activity—More than a risky ambition. JAMA Neurol2018; 75(7): 781–782.
6.
LublinFDReingoldSC.Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996; 46(4): 907–911.
7.
MarrieRAGarlandASchafferSA, et al. Traditional risk factors may not explain increased incidence of myocardial infarction in MS. Neurology2019; 92: e1624–e1633.
8.
QuillTEAbernethyAP.Generalist plus specialist palliative care—Creating a more sustainable model. N Engl J Med2013; 368(13): 1173–1175.
9.
SleemanKEHoYKVerneJ, et al. Place of death, and its relation with underlying cause of death, in Parkinson’s disease, motor neurone disease, and multiple sclerosis: A population-based study. Palliat Med2013; 27(9): 840–846.
10.
VanopdenboschLOliverD.Neurology and palliative care: A barriers analysis. Neurology2015; 84(Suppl. P3): 301.
